Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
How MiNK stole the NK T show
A single but durable stable disease sends the microcap's stock up 730%.
Another first-in-human mystery from Merck
MK-8294 starts phase 1, but its mechanism is anybody's guess.
The FDA's "radical transparency", up to a point
A newly published cache of CRLs includes six novel oncology drugs.
AbbVie steps up for Glenmark's multispecific
The deal for ISB 2001 is worth $700m up front.
